Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals ALXN - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders - in ...

The stock of Alexion Pharmaceuticals (NAS:ALXN, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value ...

The stock of Alexion Pharmaceuticals (NAS:ALXN, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors will be delighted, with the company turning in some strong numbers with its latest results. It was a solid earnings report, with revenues and ...

AstraZeneca will pay $39 billion to acquire Alexion in an immunology-driven deal that drives the British drugmaker closer to CEO Pascal Soriot's $40 billion revenue goal by 2023. (AstraZeneca) () Just ...

Hello. This is the STXBP1 Japan Patient Family Association. Today, we would like to summarize our thoughts on the issue of ...

The patents for Alexion's blockbuster therapy are expiring early. Putting the market dominance of its main sales generator at risk. However, a more potent drug from the company is slowly taking its ...

Alexion, on track to being acquired by AstraZeneca, plans to reach $9 billion to $10 billion sales by 2025. (Alexion) Toward the end of 2020, AstraZeneca splashed out $39 billion for Alexion to expand ...